Efficacy of ozone adjuvant therapy in COVID-19 patients: A meta-analysis study

Mehdi Jafari-Oori¹, Amir Vahedian-azimi², Kobra Ghorbanzadeh³, Elham Sepahvand⁴, Manijeh Dehi⁵, Abbas Ebadi⁶ and Mortaza Izadi⁷*

¹Atherosclerosis Research Center, Faculty of Nursing, Baqiyatallah University of Medical Sciences, Tehran, Iran, ²Trauma Research Center, Nursing Faculty, Baqiyatallah University of Medical Sciences, Tehran, Iran, ³Department of Nursing, Khalkhal University of Medical Sciences, Khalkhal, Iran, ⁴Department of Health Sciences, Maragheh University of Medical Sciences, Maragheh, Iran, ⁵Social Determinants of Health Research Center, Poledokhtar School of Nursing, Lorestan University of Medical Sciences, Lorestan, Iran, ⁶Department of Nursing, Maragheh University of Medical Sciences, Maragheh, Iran, ⁷Faculty of Nursing, Behavioral Sciences Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran, ⁸Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran

Introduction: Using ozone therapy to manage COVID-19 patients has been accompanied by conflicting results in prior studies. Therefore, we aimed to widely assess the effects of ozone as adjuvant therapy in COVID-19 patients.

Methods: PubMed, Scopus, Web of Science, Cochrane, ProQuest, Springer, and Sage journals were searched systematically until April 2022. Mortality rate, ICU admission, hospital-length stay, negative PCR, pulmonary, renal, and hepatic functions, as well as inflammatory and blood systems were pooled to compare the efficacy of ozone as adjacent therapy (OZ) and standard treatment (ST). Analyses were run with the random/fixed models, subgroup analysis, funnel plot, and sensitivity analysis using comprehensive meta-analysis (CMA) software version 2.0.

Results: The results of four randomized clinical trials (RCTs) and four case-control studies with a total of 371 COVID-19 positive patients were analyzed. The OZ group patients had a shorter length of hospital stay (P > 0.05), lower ICU admissions (P > 0.05), and lower mortality rates (P < 0.05) than the ST group cases. After treatment, 41% more COVID-19 patients had negative PCR tests than the ST group (P < 0.05). Serum creatinine and urea levels were not modified in either group (P > 0.05). Moreover, except for albumin serum levels, which decreased significantly in the OZ group, serum bilirubin, ALT, and AST were not modified in either group (P > 0.05). Both arms did not show a decrease in C-reactive protein blood levels (P > 0.05), but the OZ group showed a significant modification in LDH serum levels (P < 0.05). Unlike the d-dimer and WBC serum levels (P > 0.05), platelet levels were increased in the OZ group (P < 0.05). No negative side effects were demonstrated in either group.

Conclusion: Ozone therapy was effective significantly on PCR test and LDH serum levels, as well as mortality based on overall estimation.
Concerning the length of hospital stay and ICU admissions, although the results were insignificant, their effect sizes were notable clinically. More RCT studies are needed to show the efficacy of ozone therapy on other studied variables.

KEYWORDS
COVID-19, ozone therapy, standard treatment, systematic review, meta-analysis

Introduction

COVID-19 was initially detected in Wuhan, China, in December 2019. The World Health Organization (WHO) named the pandemic an international public health concern (1–3). COVID-19 has caused more than 570 million cases and 6 million deaths worldwide until July 24, 2022 (4).

Various adjuvant therapies have been used to treat patients with COVID-19, so far, efforts are still continuing to discover the most effective therapy (5, 6). One such adjunctive treatment that has been previously investigated for COVID-19 is ozone therapy (7).

The COVID-19 infection causes an inflammatory response in the lungs, heart, kidneys, and other organs (8). Ozone (O3) has a molecular weight of 48 and a density one and a half times that of oxygen (9). It is a disinfectant gas that boosts the immune system, inhibits viruses from reproducing, and depending on its concentration, has powerful antioxidant effects (10, 11). Ozone reduces inflammation by acting on interleukins, raises ATP in red blood cells, and enhances RBCs’ access to oxygen (12). Additionally, it is an excellent biocidal agent due to its strong oxidizing properties, and its effectiveness has been confirmed in bacteria, fungi, and viruses (13). Ozone can have great potential for improving oxygenation in COVID-19 patients due to its antioxidant, antiviral, and anti-inflammatory characteristics (14). It is administered by various methods, like major and minor hemo-therapy, insufflation, and other methods (15).

The effectiveness of ozone on COVID-19 patients has been studied in several studies (15–17). However, the outcomes of these studies were conflicting, making it difficult for physicians to make a decision on whether to prescribe it or not. Additionally, in several review articles, ozone therapy in COVID-19 patients has been studied; however, these review studies (18–20) except one (21) were not systematic reviews and meta-analyses, and mostly focused on the mechanism of effect. However, in a recent meta-analysis study by Budi et al. (21), the limited outcomes were measured, and the effect of ozone on PCR results, disease severity, pulmonary, hepatic, renal, and hematology profiles have not been addressed. Also, in this study, case reports were also included, while in the present study, only studies that had control and intervention groups were included in the analysis.

Considering the conflicting results in prior studies, the application of ozone in COVID-19 patient’s treatment are remained controversial. Therefore, researchers decided to conduct a systematic review and meta-analysis study to measure the effect of ozone therapy on various factors such as mortality, ICU admission, hospital-length stay, pulmonary, renal, and hepatic functions, as well as inflammatory and blood systems in COVID-19 patients.

Methods

This systematic review and meta-analysis study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for systematic reviews and meta-analyses (22). This study’s protocol was registered in PROSPERO with a registration number of CRD42022325049.

Eligibility criteria

The eligible articles were related to patients with positive RT-PCR (reverse transcriptase-polymerase chain reaction) regardless of the disease severity, included ozone as adjuvant therapy, and published in national or international journals with full text in English or Persian languages from December 1990 to April 2022. Randomized controlled trials (RCTs), clinical trials, cohort studies, and case-control studies with control and intervention groups were included. One group’s studies like case series and case reports were excluded. Furthermore, we excluded review articles, unrelated articles, inaccessible, and duplications.

Search strategy and study selection

Initially, MeSH and text terms were identified, and then syntaxes were made according to databases. Two authors (ES and KG) independently searched PubMed,
Scopus, the Web of Science, the Cochrane Database of Systematic Reviews, trial registries (ClinicalTrials.gov), and the internal database from December 1990 to April 2022. Google Scholar and Google were also screened as search engines. In addition, reference lists of related articles (backward search) and studies that cited them (forward search) as well as gray literature were reviewed. While conducting a literature search, any controversial ideas were solved by all authors. Selection of studies was fulfilled through conducting three stages of duplicate checking by the reference manager, screening title and abstract to ensure relevancy, and finally screening full text articles to exclude unrelated articles (Figure 1).

**Data extraction**

Two review authors (MJ-O and KG), independently extracted the following items: first author's name, study design, country, sample size, disease severity, types of standard treatments, administration technique of ozone therapy, duration and dose of ozone therapy, adverse effects, and quality score.

**Quality assessment**

The revised Cochrane risk-of-bias tool for randomized trials (RoB-2) was used for risk of bias assessment for randomized trials. Bias is judged as high, low, or unclear in terms of selection, performance, attrition, reporting, and other biases (23). We also Newcastle-Ottawa Scale (NOS) to assess case-control studies. Two authors checked the quality of the studies independently (MJ-O and MD), and any discrepancy was resolved by the third author with more capability to review the study (MI).

**Data analysis**

To summarize the data, various effect sizes were used, such as risk ratio (RR), risk difference (RD), and mean difference (MD) with 95% confidence intervals. A meta-analysis was run...
using random effects and fixed effect regarding the level of heterogeneity. The heterogeneity levels were categorized as 0–25, 26–50, 51–75, and 75–100%, indicating low, moderate, and high between-study heterogeneity, respectively (24). In the analyses of homogenous (I < 50% and P > 0.05) and heterogeneous (I > 50% and P < 0.05) data, the fixed-effects and random-effects models were used, respectively (25). We were unable to assess publication bias since at least 10 studies are required to assess publication bias (26). A sensitivity analysis using the leave-one-out method was used to analyze the effect of one single research effect on the total pooled estimation. CMA software was used to analyze the data. The p-value for statistical significance was set at 0.05. We included both RCTs and case-control studies in a meta-analysis. In many cases, the advantages of integrating both observational studies and RCT in a meta-analysis may outweigh the disadvantages, therefore observational studies shouldn’t be simply excluded (27, 28).

Results

Study selection

From databases and manual searches, a total of 1,970 articles were retrieved. Following duplicates check and titles and abstracts screening, 121 articles were remained. After a full-text review, eight studies (2, 6, 8, 17, 29–32) were included in the final analysis. The study selection process is shown in the PRISMA flow chart (Figure 1).

Study characteristics

Four of the eight studies were RCTs (6, 17, 29, 31), while the remaining four were case-control studies (2, 30, 32, 33). Overall, 371 COVID-19 patients were included, of which 213 and 157 were in the intervention group [Ozone therapy + standard treatment (OZ arm)] and control group [standard treatment (ST)] as a standard, respectively. The lowest (treatment (OZ arm)) and control group (standard treatment) were in the intervention group [Ozone therapy + standard treatment]. COVID-19 patients were included, of which 213 and 157 remaining four were case-control studies (2, 30, 32, 33). Overall, 371 COVID-19 patients were included, of which 213 and 157 were in the intervention group [Ozone therapy + standard treatment (OZ arm)] and control group [standard treatment (ST)] as a standard, respectively. The lowest (treatment (OZ arm)) and control group (standard treatment) were in the intervention group [Ozone therapy + standard treatment].

Studies’ risk of bias

The study’s risk of bias result indicated that three RCTs were high-quality (6, 17, 31), whereas one seemed to has a little risk of bias (29) regarding the Cochrane’s Risk of Bias 2 (RoB2) assessment (Supplementary Table 1). Furthermore, based on the NOS, three-quarters of case-control studies were high-quality (30, 32, 34), and the other one was medium-quality (2) (Supplementary Table 2).

Comparison of the effect of ozone therapy and standard treatment for the management of COVID-19 patients

The effects of OZ and ST were assessed and compared in terms of hospital stay, ICU admission, mortality rate, renal and hepatic profiles, inflammation markers and hematology profile, Reverse transcription-polymerase chain reaction (RT-PCR), and safety parameters in COVID-19 patients, which are reported in the following.

Length of hospital stay

The length of hospital stay was reported in two RCTs (17, 31) and three case-control studies (30, 32, 34). The sub-group analysis indicated that patients who were treated with Ozone as an adjuvant therapy were hospitalized less than ST-treated patients both in RCT studies (MD = −0.69 day, P = 0.46, I² = 0.88, random-effects) and case-control (MD = −4.79 days, P = 0.30, I² = 0.53, random-effects) studies; however, the results were statistically insignificant. Additionally, the overall analysis of both study types in a single mate-analysis indicated that the Ozone treated patients were hospitalized insignificantly about 1 day less than the standard treated patients (MD = −1.18 day, P = 0.46, I² = 0.69, random-effects) (Figure 2). Statistical insignificance and heterogeneity were maintained after the run of the leave-one-out sensitivity analysis. Egger’s regression intercept test was −1.72 (p = 0.120), indicating no publication bias (Supplementary Figure 1).

ICU admission

ICU admission were reported in the three RCTs (6, 29, 31) and three case-control (2, 32, 34) studies. As Figure 3 show,
| Author                  | Study design | Country | Sample  | Disease severity                  | Types of Baseline treatment                                                                 | Type of ozone administration                                                                 | Duration and dose of ozone therapy                                                                 | O3 adverse effect | Outcome type                                                                                                                                 |
|------------------------|--------------|---------|---------|-----------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Çolak et al. (2)       | Case-control study | Turkey  | 55 patients (OZ + ST: 37, ST: 18) | Patients with respiratory system complaints. | Hydroxychloroquine, enoxaparin, favipiravir, and antibiotics | Ozone major autohemotherapy (MAH) | Seven sessions (one session per day), in a volume of 100 mL and a concentration of 30 µg/mL.  | No               | Mortality, ICU admission                                                                                                                  |
| Shah et al. (7)        | RCT          | India   | 60 patients (OZ + ST: 30, ST: 30) | Mild to moderate score based on NEWS score | Indian Council of Medical Research (ICMR) protocol | Ozonezed rectal insufflation and [minor auto haemotherapy (MIAHT)] | 10 days, 40 A µg/ml ozone in the dose of about 150 ml twice daily as a rectal insufflation, and 2–3 ml venous blood along with 5 ml ozone at 25 A µg/ml | No               | Clinical features, NEWS score (RT-PCR), inflammatory markers, the requirement of advanced care, and metabolic profiles |
| Fernández-Cuadros et al. (29) | Case-control study | Spain  | 28 patients (OZ + ST: 14, ST: 14) | Severe COVID-19 | Antivirals, corticosteroids, antibiotics, anticoagulants, and anti-IL-6 | Rectal ozone, 8 sessions (1 session/day) | for 5 to 10 days, insufflation of a volume of 150 mL at a concentration of 35 µg/mL. | No               | Clinical, biochemical, radiological Taylor's scale, hospitalization length of stay, ad mortality |
| Aramio et al. (28)     | RCT          | Italy   | 28 patients (OZ + ST: 14, ST: 14) | Respiratory supported with venturi mask (VMK) or HFNC, or CPAP | Antivirals, corticosteroids, and antibiotics | MAH daily double treatment until 7 days | Seven days, A total of 15 × 103 mcg of ozone was the daily | No               | Tracheal intubation, mortality, hematological parameters                                                                                   |
| Dengiz et al. (16)     | RCT          | Turkey  | 30 patients (OZ + ST: 15, ST: 15) | PCR positive patients admitted to the emergency department | Antivirals, corticosteroids, and antibiotics. | Ozone inhalation | Five days, three sessions applied for 10 mins at intervals of 5 mins daily. Each session: 0.2 ppm ozone for 3 days, 200 mL of a gas mixture composed of 96% of Oxygen and 4% of ozone with a therapeutic O3 range of 40 µg/mL of gas per mL of blood | No               | Clinical and biochemical tests                                                                                                                                 |
| Sozio et al. (30)      | RCT          | Italy   | 92 patients (OZ + ST: 48, ST: 44) | Mild to moderate pneumonia based on SIMEU clinical phenotype (2 or 3) | Antivirals, corticosteroids, and antibiotics | MAH | Three days, 200 mL freshly prepared ozonized saline intravenously over 1 h once a day for 8 days along with standard medical treatment | No               | Hospital stay; improved chest imaging, oxygen therapy, CPAP, tracheal intubation, and inflammatory response |
| Tascini et al. (31)    | Case-control study | Italy  | 60 patients (OZ + ST: 30, ST: 30) | Moderate pneumonia based on SIMEU clinical phenotype (2 or 3) | Antivirals, corticosteroids, and antibiotics | MAH | Five days, 200 mL blood of oxygen-ozone mixture with a 40 µg/mL ozone concentration | No               | Clinical and biochemical tests                                                                                                                                 |
| Hernandez et al. (33)  | Case-control study | Spain  | 18 patients (OZ + ST: 9, ST: 9) | Severe COVID-19 pneumonia | Antivirals, corticosteroids, and antibiotics | MAH | Five days, 200 mL blood of oxygen-ozone mixture with a 40 µg/mL ozone concentration | No               | Time from hospital admission to clinical improvement                                                                                                                                 |
although RR of ICU admission in RCTs (RR = 0.44, \(P = 0.14\), \(I^2 = 0\), fixed-effect) and case-control (RR = 0.69, \(P = 0.43\), \(I^2 = 0\), fixed-effect) studies were less in the Ozonized patients than the ST group, but the differences were not statistically significant. Similarly, the overall RR of ICU admission was in favor of OZ group, but the result was insignificant (RR = 0.57, \(P = 0.123\), \(I^2 = 0\), fixed-effect). The significance of the results was not established by the sensitivity analysis. There was no evidence of publication bias in the funnel plot (Egger’s regression intercept = 0.37, \(P = 0.371\); Supplementary Figure 2).

**Mortality**

Mortality was measured in three RCTs (6, 29, 31) and four case-control studies (2, 30, 32, 34). As indicated in Figure 4, the pooled mortality of case-control studies revealed that the patients in the Ozone group had significantly about 0.76% less mortality than the patients in the ST group (OR = 0.23, \(P = 0.000\), \(I^2 = 0\), fixed-effect). However, according to the pooled estimation of RCTs, Ozone therapy was not associated significantly with odds of mortality than the standard therapy (OR = 0.73, \(P = 0.461\), \(I^2 = 0\), fixed-effect). When leave-one-out sensitivity analyses were carried out, neither heterogeneity nor statistical significance were affected. Considering the overall pooled estimation, standard treatment patients had high odds of mortality than the Ozone therapy patients (OR = 0.37, \(P = 0.000\), \(I^2 = 30.48\), fixed-effect). The funnel plot and Egger’s test showed no publication bias (Egger’s regression intercept = 0.35, \(P = 0.851\); Supplementary Figure 3).

**RT-PCR**

Two RCTs examined RT-PCR (6, 17). RT-PCR was measured two times at day 5 and day 10 after finishing of Ozone therapy in the study of Shah et al. (6). The results of those both times results were included. The number of COVID-19 patients who revealed negative PCR in the OZ arm was significantly higher than the patients in the ST group (RD = 0.41, \(P = 0.004\), I2 = 81.44, random-effects) (Figure 5). The leave-one-out sensitivity analysis displayed that the statistical significance was canceled if Shah et al., Day 10 (6) was removed. As the Supplementary Figure 4 shows, there was no publication bias (Egger’s regression intercept = 5.61, \(P = 0.671\)).

**Renal profile**

Two RCTs reported serum creatinine (mg/dL) and Urea (mg/dL) level changes before and after of intervention in the both OZ and ST arms (6, 29). There was an insignificant reduction in serum creatinine levels among patients receiving ozone therapy (MD = 0.01 mg/dL, \(P = 0.634\), I2 = 0, fixed-effect), whereas for the ST group, this change was significant, suggesting that serum creatinine levels declined significantly after the intervention (MD = 0.17 mg/dL, \(P = 0.000\), I2 = 52, random-effects) (Figure 6A). Additionally, as shown in Figure 6B, in the OZ arm, the pooled MD of serum level of BUN increased non-significantly (MD = 0.58 mg/dL, \(P = 0.298\), I2 = 98, random-effects), indicating that ozone therapy resulted in elevated serum urea levels in patients. A significant increase in serum urea levels was also observed after treatment in the ST group (MD = 2.53 mg/dL, \(P = 0.000\), I2 = 00, fixed-effect).

**Hepatic profile**

The changes of hepatic markers levels including albumin (g/dL), bilirubin (mg/dL), AST [international units per liter (IU/L)], and ALT (IU/L) were measured in two RCTs (6, 29). Regarding to the albumin, a significant change was exhibited in the serum albumin levels. However, the albumin level decreased in the OZ group (MD = 0.26 g/dL, \(P = 0.007\), I2 = 0, fixed-effect), and increased in the ST group (MD = 0.61 g/dL,
P = 0.007, I² = 0, fixed-effect) (Figure 7A). Further, neither in the OZ (MD = 0.11 mg/dL, P = 0.150, I² = 82.31, random-effects) nor in the ST (MD = 0.18 mg/dL, P = 0.398, I² = 89.31, random-effects) groups, the interventions were not associated with total bilirubin levels changes (Figure 7B). Likewise, the serum AST level was increased non-significantly in the OZ group (MD = -4.93 IU/L, P = 0.066, I² = 0, fixed-effect) and but decreased in the ST group (MD = 10.70 IU/L, P = 0.614, I² = 82.36, random-effects) (Figure 7C). Moreover, a non-significant decrease in ALT levels was observed in the both
the OZ (MD = 19.24 IU/L, \( P = 0.368, I^2 = 77.46\), random-effects) and ST (MD = 35.81 IU/L, \( P = 0.484, I^2 = 86.57\), random-effects) groups (Figure 7D).

### Inflammation markers

A pre- and post-intervention analyses of inflammation markers including CRP (mg/L) and LDH (units per liter [U/L]) were performed in three RCTs (6, 17, 29). In the Ozone-treated arm, a decrease in the serum CRP levels was observed (MD = 0.04 mg/L, \( P = 0.966, I^2 = 64.76\), random-effects), whereas, a reverse change was detected in the ST group (MD = -0.15 mg/L, \( P = 0.866, I^2 = 79.12\), random-effects) (Figure 8A). The sensitivity analysis showed that the study of Aramio et al. (29), had considerable effect on the polled CRP serum level changes. Both arms reached zero heterogeneity after removing it, but statistically significant levels were not changed. Further, a significant modification in the LDH serum levels was seen in the OZ group (MD = -44.72 U/L, \( P = 0.001, I^2 = 81.44\), random-effects). Likewise, a significant increase in the D-dimer levels was shown in the ST-treated arm (MD = 178.55 ng/mL, \( P = 0.148, I^2 = 2.13\), fixed-effect) (Figure 9A). The WBC serum levels both in the pre and post intervention in both groups were in the normal range (4.5ñ11.0 \( \times 10^9 \)/L). Neither the Ozone therapy (MD = 0.24 \( \times 10^9 \)/L, \( P = 0.487, I^2 = 2.13\), fixed-effect) nor standard medications (MD = 0.33 \( \times 10^9 \)/L, \( P = 0.422, I^2 = 0\), fixed-effect) had a significant effect on the serum WBC level (Figure 9B).

### Hematology profiles

Serum D-dimer (ng/mL) was assessed in two RCTs (17, 29). Also, WBC (\( 10^9 \)/L) and platelets (\( 10^9 \)/L) serum level were reported in two RCTs (29, 31) and three RCTs (17, 29, 31), respectively. In the OZ group, D-dimer levels decreased, but the change value was not statistically significant (MD = -34.94 ng/mL, \( P = 0.0201, I^2 = 64.36\), random-effects). Likewise, an insignificant increase in the D-dimer levels was shown in the ST-treated arm (MD = 178.55 ng/mL, \( P = 0.148, I^2 = 2.13\), fixed-effect) (Figure 9A). The WBC serum levels both in the pre and post intervention in both groups were in the normal range (4.5ñ11.0 \( \times 10^9 \)/L). Neither the Ozone therapy (MD = 0.24 \( \times 10^9 \)/L, \( P = 0.487, I^2 = 2.13\), fixed-effect) nor standard medications (MD = 0.33 \( \times 10^9 \)/L, \( P = 0.422, I^2 = 0\), fixed-effect) had a significant effect on the serum WBC level (Figure 9B). Finally, both the OZ (MD = 69.33 \( \times 10^3 \) per microliter of blood, \( P < 0.05, I^2 = 86.50\), random-effects) and ST (MD = 62.51 \( \times 10^3 \) per microliter of blood, \( P < 0.05, I^2 = 86.50\), random-effects)
### A. Serum albumin level changes in the OZ and ST groups

| Group by | Study name | Statistics for each study | Difference in means and 95% CI | Difference Standard Lower Upper Relative Relative | Total weight |
|----------|------------|---------------------------|--------------------------------|--------------------------------------------------|--------------|
| **OZ group** | Shah et al (OZ) | -0.270 0.099 -0.350 -0.190 -0.464 -0.276 -3.739 0.036 10 | | | 99.38 |
| **OZ group** | Aramio et al (OZ) | 0.540 1.201 0.590 -0.020 1.202 0.424 0.489 0.999 14 | | | 87.95 |
| **OZ group** | Shah et al (ST) | -0.035 0.098 0.020 -0.040 -0.020 -0.025 1.270 0.617 14 | | | 19.13 |
| **ST group** | Shah et al (ST) | 0.520 0.044 0.020 -0.030 -0.010 0.786 14.199 0.617 14 | | | 99.87 |

### B. Serum bilirubin level changes in the OZ and ST groups

| Group by | Study name | Statistics for each study | Difference in means and 95% CI | Difference Standard Lower Upper Relative Relative | Total weight |
|----------|------------|---------------------------|--------------------------------|--------------------------------------------------|--------------|
| **OZ group** | Shah et al (OZ) | 0.000 0.101 0.000 -0.038 0.038 0.000 1.000 30 | | | 58.33 |
| **OZ group** | Aramio et al (OZ) | 0.270 0.112 0.013 0.051 0.489 2.413 0.016 14 | | | 41.67 |
| **ST group** | Shah et al (ST) | -0.312 0.040 0.020 -0.390 -0.234 -1.784 0.000 30 | | | 52.76 |
| **ST group** | Aramio et al (ST) | -0.050 0.073 0.005 -0.194 0.094 -0.683 0.495 14 | | | 47.24 |

### C. Serum AST level changes in the OZ and ST

| Group by | Study name | Statistics for each study | Difference in means and 95% CI | Difference Standard Lower Upper Relative Relative | Total weight |
|----------|------------|---------------------------|--------------------------------|--------------------------------------------------|--------------|
| **OZ group** | Shah et al (OZ) | -5.870 3.155 9.957 -12.054 0.314 -1.860 0.063 30 | | | 72.48 |
| **OZ group** | Aramio et al (OZ) | -2.480 5.120 26.217 -12.515 7.555 -0.484 0.628 14 | | | 27.52 |
| **ST group** | Shah et al (ST) | -7.240 3.022 9.135 -13.164 -1.316 -2.395 0.017 30 | | | 97.14 |
| **ST group** | Aramio et al (ST) | 3.580 17.605 309.953 1.074 70.086 2.021 0.043 14 | | | 43.55 |

### D. Serum ALT level changes in the OZ and ST groups

| Group by | Study name | Statistics for each study | Difference in means and 95% CI | Difference Standard Lower Upper Relative Relative | Total weight |
|----------|------------|---------------------------|--------------------------------|--------------------------------------------------|--------------|
| **OZ group** | Shah et al (OZ) | 2.060 3.180 10.111 -4.172 8.292 0.648 0.517 30 | | | 60.74 |
| **OZ group** | Aramio et al (OZ) | 45.830 20.535 421.687 5.582 86.078 2.232 0.026 14 | | | 39.26 |
| **ST group** | Shah et al (ST) | -9.120 5.250 27.566 -19.411 1.171 -1.737 0.082 30 | | | 56.45 |
| **ST group** | Aramio et al (ST) | 94.060 37.440 1401.768 20.679 167.441 2.512 0.012 14 | | | 43.55 |

### FIGURE 7

The forest plots of hepatic profile changes (A–D) before and after the interventions in the both groups.
groups had a significant increase in platelet count, after the interventions (Figure 9C). No publication biases were observed in platelet reported studies (Egger's regression intercept = −2.45, \( p = 0.81 \); Supplementary Figure 4). The degree of heterogeneity did not change when a leave-one-out sensitivity analysis was performed.

### Discussion

The therapeutic efficacy of OZ in combination with ST was evaluated in COVID-19 patients in this study. Despite the fact that our meta-analysis study demonstrated that ozone adjuvant therapy improved clinical variables and laboratory biomarkers in COVID-19 patients, except for mortality rates, PCR tests, and serum levels of LDH, its effects were insignificant. From a clinical perspective, the estimated effect sizes of the variables can be notable, regardless of the significance level.

Ozone treatment was found to be more beneficial than usual care in COVID-19 patients with severe respiratory symptoms (35). According to Franzini’s research, O2 saturation increased from 85 to 95% after an 8.6-day ozone treatment (13). Aramio also discovered that the demand for ventilator support was moderately reduced in the ozone group (reduced need for CPAP, high-flow nasal cannula, or venturi masks) (29). The same result was observed in Schwartz’s study, in which supplemental oxygen usage dropped from 68 to 24% in the OZ arm (36). The amelioration of bilateral radiographic pneumonia based on Taylor’s radiologic scale could be one cause for enhancing O2 saturation and minimizing the demand for O2 supply in the OZ arm (35, 36).

Other studies have found that the OZ arm’s hospital stay is shorter than the ST group’s, which supports our findings (16, 33, 36).

Similarly, previous studies have found that COVID-19 patients who received ozone therapy had a reduced mortality rate than ST patients (8, 32, 36). According to our findings, ozone's potential antiviral activity can aid in the early reduction and clearance of COVID-19, resulting in less virus infiltration.
### A

| Group by | Group type | Study name | Statistics for each study | Difference in means and 95% CI | p-Value | Total weight |
|----------|------------|------------|---------------------------|-------------------------------|---------|--------------|
|          |            |            |                           |                               |         |              |
| OZ group | Aramio et al (OZ) | 48.200 | 20.987 | 440.474 | 7.065 | 89.335 | 2.297 | 0.022 | 14 | 22.16 |
| OZ group | Dengiz et al (OZ) | 30.270 | 12.369 | 152.997 | 6.027 | 54.513 | 2.447 | 0.014 | 15 | 26.08 |
| OZ group | Sozio et al (OZ) | 80.000 | 13.112 | 171.913 | 54.302 | 105.698 | 6.101 | 0.000 | 48 | 25.78 |
| OZ group | Sozio et al (OZ) | 116.000 | 12.637 | 159.683 | 91.233 | 140.767 | 9.180 | 0.000 | 48 | 25.98 |

### B

| Group by | Group type | Study name | Statistics for each study | Difference in means and 95% CI | p-Value | Total weight |
|----------|------------|------------|---------------------------|-------------------------------|---------|--------------|
|          |            |            |                           |                               |         |              |
| ST group | Aramio et al (ST) | 40.100 | 16.841 | 283.623 | 7.092 | 73.108 | 2.381 | 0.017 | 14 | 24.74 |
| ST group | Dengiz et al (ST) | 7.110 | 18.924 | 358.122 | -29.981 | 44.201 | 0.376 | 0.707 | 15 | 23.81 |
| ST group | Sozio et al (ST) | 96.000 | 13.067 | 170.750 | 70.389 | 121.611 | 7.347 | 0.000 | 44 | 26.29 |
| ST group | Sozio et al (ST) | 102.000 | 15.851 | 251.259 | 70.932 | 133.068 | 6.435 | 0.000 | 44 | 25.16 |

### C

| Group by | Group type | Study name | Statistics for each study | Difference in means and 95% CI | p-Value | Total weight |
|----------|------------|------------|---------------------------|-------------------------------|---------|--------------|
|          |            |            |                           |                               |         |              |

![Figure 9](https://example.com/figure9.png)

The forest plots of hematology profile changes before and after interventions in the both arms.

and harm to organs (37). Additionally, some other one-group trials’ results supported the statistically significant effect of OZ therapy in COVID-19 patients. For example, Schwartz et al. reported that no one who received treatment with ST + OZ passed away temperature (36). Alhmadi Hekmat in his study (38) demonstrated no significant change in mortality after OZ therapy. An increase in mortality could result from the administration of the medication at a late stage of the disease or when multi-organ dysfunction is present.

In terms of renal indicators, there was no significant change in the OZ arm, but a minor significant improvement in the ST group. In this meta-analysis, the effect of ozone therapy on creatinine level was investigated in two primary studies (6, 29). In Shah et al.’s study, serum creatinine level at baseline was 0.78 ± 0.27, which declined to 0.77 ± 0.17 after ozone therapy (6). Similarly, Aramio et al. indicated that the creatinine level was 0.84 ± 0.24 and 0.83 ± 0.18 at baseline and 7 days after starting ozone therapy, respectively (29). In the control group, this change was from 1 ± 0.14 to 0.80 ± 0.13 in the Shah et al.’s study (6), and from 0.97 ± 0.28 to 0.85 ± 0.22 in the Aramio et al.’s study (29). In both studies, creatinine levels were at a normal range in both groups before and after the interventions. Likewise, a study showed insignificant serum creatinine level change after OZ therapy (16).

Regarding BUN, of three studies (6, 17, 35), only in one study (35), BUN serum level was over the upper limit, but it modified slightly in favor of ozone. As a result of these findings, ozone therapy may have a beneficial effect on kidney function.

On the hepatic profile, serum albumin level was slightly amended in the OZ group but significantly increased abnormally over the upper limit in the ST group, reflecting more hepatic damage. Also, the total bilirubin level was in the normal range in both groups before and after the interventions.
normal range before and after the interventions in both groups. In light of these findings, it is currently difficult to determine what effect ozone therapy can have on the total bilirubin level. Likewise, the AST level was in the normal range both pre-and post-intervention in the OZ arm but did not change significantly after ozone therapy, whereas it had increased to an abnormal upper level in the ST group. Similarly, although the amount of ALT was insignificantly increased abnormally in both groups; however, this rate of change was higher in the ST group than in the OZ arm. Hepatic profiles were assessed only in two RCT studies (6, 29); more research is needed to get a more conclusive result.

In terms of inflammatory indicators, the level of CRP and LDH in the ozone group decreased dramatically. In terms of magnitude, this amount of reduction was more than the ST group. The rate of LDH reduction was not statistically significant in the ST group. Other research has shown that ozone can modify interferons, cytokines, and inflammation biomarkers (39, 40). In one other group experimental studies, contrary to findings of Franzini et al. (16), Sharma et al. (14), administered ozone adjuvant therapy on 10 patients intravenously over 1 h once a day for 8 days, the results showed that the change in LDH was borderline statistically not significant ($p = 0.058$).

In the case of the hematological profile, the amount of WBC was in the normal range in both groups before and after the intervention, and the interventions had no significant influence on it. However, platelet levels increased significantly and equally in both intervention groups. Bocchi claims that ozone promotes the differentiation of white blood cells and platelets in addition to activating stem cells (41).

In terms of safety parameters, this review found no evidence of a harmful effect from ozone, which is consistent with a manuscript that found just 0.7 recorded adverse reactions per 100,000 treatments (42). Also, ozone did not negatively affect any extra pulmonary organs, such as the hepatic, kidneys, lipid profile, or blood cell profile (6). Limitation

This meta-analysis included a small number of studies, which was just eight studies. Also, ozone was administered by autohemotherapy, rectal insufflation, and inhalation, which may lead to different levels of effect. Further studies are needed to provide estimated effect measures based on administration type. Similarly, only non-mechanically ventilated patients were in the included RCT studies. Based on the positive therapeutic effect of ozone in COVID-19 patients, it appears that the effect of ozone in critically sick patients, who are intubated, should be examined as well. Because the goal of our analysis was to compare the therapeutic effects of ozone to standard treatment, we only included RCTs with OZ and ST arms and excluded studies with alternative designs such as case reports, case series, and single-group semi-experimental studies. We were unable to undertake subgroup analysis or meta-regression to control and reduce heterogeneity between findings due to the limited number of RCT trials. Despite the mentioned limitations, this is presently the first comprehensive meta-analysis study that has been able to examine a wide range of clinical and biochemical effects of ozone, as well as identify knowledge gaps that should be addressed by future research.

**Conclusion**

Although our study showed that, in most cases, ozone adjuvant therapy was insignificant in COVID-19 patients, the estimated effect sizes were notable. Based on the safety parameters of ozone adjuvant therapy, its administration in COVID-19 patients may result in positive results. However, more research is needed to understand the real effects of ozone adjuvant therapy on laboratory and clinical outcomes.

**Author contributions**

MJ-O, KG, ES, MD, AE, and MI: idea. MJ-O and MI: literature search. MJ-O, KG, and ES: analysis. MJ-O and AV-A: first draft of the manuscript. MJ-O, AV-A, AE, and MD: final draft of the manuscript. MJ-O, AE, and MI: supervision. All authors contributed to the article and approved the submitted version.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.1037749/full#supplementary-material
References

1. Izaei M, Cegolno L, Javanbakht M, Sarrafzadeh A, Abolghasemi H, Alisheh G, et al. Ozone therapy for the treatment of COVID-19 pneumonia: a scoping review. *Int Immunopharmacol.* (2022) 92:107307. doi: 10.1016/j.intimp.2020.107307

2. Çolak Ş, Genç Yavuz B, Yavuz M, Orçelik B, Öner M, Özgültekin A, et al. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19. *Int J Clin Pract.* (2021) 75:14321. doi: 10.1111/ijcp.14321

3. Martins RB, Castro IA, Pontelli M, Souza JP, Lima TM, Melo SR, et al. SARS-CoV-2 inactivation by ozonated water: a preliminary alternative for environmental disinfection. *Ozone Sci Eng.* (2021) 43:108–11. doi: 10.1080/01919512.2020.1842998

4. World Health Organization [WHO]. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization (2020).

5. Merks P, Religioni U, Bilimkin K, Bogusz J, Juszczynski G, Barańska A, et al. Ozone desinfection of community pharmacies during the COVID-19 pandemic as a possible preventive measure for infection spread. *Med Pr.* (2021) 72:529–34. doi: 10.1075/mp.5893.01091

6. Shah M, Captain J, Vaidya V, Kulkarni A, Valangkar K, Nair PM, et al. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: a phase 1/11 randomized control trial (SEOT study). *Int Immunopharmacol.* (2021). 91:107301. doi: 10.1016/j.intimp.2020.107301

7. Cattel F, Giordano S, Bertiond C, Lupia T, Corcione S, Scaldaferri M, et al. Ozone therapy in COVID-19: a narrative review. *Virus Res.* (2021) 291:198207. doi: 10.1016/j.viruses.2020.198207

8. Hernández A, Vítilas M, Isidoro T, Vilas F. Potential role of oxygen-ozone therapy in treatment of COVID-19 pneumonia. *Am J Case Rep.* (2020) 21:e925849. doi: 10.15634/ACR.925849

9. Sunnen GV. Ozone in medicine: overview and future directions. *J Adv Med.* (1988) 1:159–74.

10. Sallustio F, Caridine G, Voccola S, Pecerno A, Porcaro P, Gesualdo L. Ozone therapy attunes NF-κB-mediated local inflammatory response and activation of TH17 cells in treatment for postrs. *Int J Biol Sci.* (2020) 16:1833. doi: 10.7187/jibs.41940

11. Zheng Z, Dong M, Hu K. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19. *J Med Viral.* (2020) 92:2348–50. doi: 10.1007/jmiv.2020.00001

12. Zeng J, Lei L, Zeng Q, Yao Y, Wu Y, Li Q, et al. Ozone therapy ameliorates NF-κB-mediated local inflammatory response and activation of TNFα/IL-6 and IL-10 in COVID-19 patients. *Int J Biol Sci.* (2020) 16:1833. doi: 10.7187/jibs.41940

13. Mazur-Panasik N, Botwina P, Kotaj A, Wooczyzna D, Pyrc K. Ozone treatment is insufficient to inactivate SARS-CoV-2 surrogate under field conditions. *Antioxidants.* (2021) 10:480. doi: 10.3390/antiox10090480

14. Sharma A, Shah M, Lahsmi S, Sane H, Captain J, Gokulchandran N, et al. Pilot study for treatment of COVID-19 in patients: moderate stage using intravenous administration of ozonized saline as an adjunct treatment registered clinical trial. *Int Immunopharmacol.* (2021) 96:107743. doi: 10.1016/j.intimp.2020.107743

15. Marini S, Maggiorotti M, Dardes N, Bonetti M, Martinelli M, Re L, et al. Oxygen-ozone therapy as an adjuvant therapy in COVID-19 patients with pneumonia during the outbreak. *Int J Adv Med.* (2021) 6:6218. doi: 10.19080/IJAM.2021.06.006

16. Shah M, Captain J, Vaidya V, Kulkarni A, Valsangkar K, Nair PM, et al. Safety of ozone therapy in treatment of COVID-19 pneumonia. *Am J Case Rep.* (2021) 29:198207. doi: 10.1016/j.viruses.2020.198207

17. Dengiz E, Özcan Ç, Göven Y, Uyar S, Ener BK, Sözen S, et al. Ozone gas applied in COVID-19 patients after intubation: a prospective randomized trial. *Int Immunopharmacol.* (2021) 90:107261. doi: 10.1016/j.intimp.2020.106879

18. Franco Z, De Monte A, Baggianelli A, De Simone P, Amato G, et al. Ozone therapy for patients with COVID-19 pneumonia: a randomized prospective study. *Eur J Intern Med.* (2021) 89:66–71. doi: 10.1016/j.ejim.2021.05.023

19. Shrier I, Bovin JF, Steele RJ, Platt RW, Furlan A, Kakuma R, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. *Am J Epidemiol.* (2007) 166:1203–19. doi: 10.1093/aje/kwm189

20. Burk-Ross S, Scheer J, Guillo S, Tubach F, Dechartres A. Meta-analyses frequently pooled different study types together: a meta-epidemiological study. *J Clin Epidemiol.* (2021) 118:18–28. doi: 10.1016/j.jclinepi.2019.01.013

21. Aramio F, Imperiale C, Tordiglione P, Ceccarelli G, Borrazzo C, Alessandri E, et al. Ozone as adjuvant support in the treatment of COVID-19: a preliminary report of prosobiotic trial. *Med Virolog.* (2021) 93:2210–20. doi: 10.1007/jmv.2021.0636

22. Fernández-Cuadros ME, Albaladejo-Florin MJ, Albano-Rabasa S, Gallego-Galiana J, Pérez-Cruz GF, Usandizaga-Elio I, et al. Compassionate use of rectal Ozone (OS) in severe COVID-19 pneumonia: a case-control study. *SN Compr Clin Toxicol.* (2021) 9:126–142. doi: 10.56499/jppres20.971_9.2.126

23. Yousefi B, Banihashemian SZ, Feyzabadi ZK, Hasanpour S, Kokhaei P, et al. Modulation of oxidative stress by ozone therapy in COVID-19 patients. *Int J Psychosocial Rehab.* (2020) 24:10577ñ88.

24. Razzaq HA, Hasan MS, Al-Dhalemy MF, Al-Silaykhee WM, Alhmadi HB, Almoez ZA. Utilization of ozone as a complementary therapy for COVID-19 patients. *Int J Psychosocial Rehab.* (2020) 24:10577–88.

25. Blanco B, Rodríguez-Esparragón F, Rodríguez-Abreu D, Martínez-Sánchez G, Llointop P, Aguaruj-Bujanda D, et al. Modulation of oxidative stress by ozone therapy
in the prevention and treatment of chemotherapy-induced toxicity: review and prospects. Antioxidants. (2019) 8:588. doi: 10.3390/antiox8120588

40. Kahle JJ, Neas LM, Devlin RB, Case MW, Schmitt MT, Madden MC, et al. Interaction effects of temperature and ozone on lung function and markers of systemic inflammation, coagulation, and fibrinolysis: a crossover study of healthy young volunteers. Environ Health Perspect. (2015) 123:310–6.

41. Bocci V. Is it true that ozone is always toxic. The end of the dogma. Toxicol Appl Pharmacol. (2006) 216:493–504. doi: 10.1016/j.taap.2006.06.089

42. Valdenassi L, Franzini M, Ricevuti G, Rinaldi L, Gallofro A, Tirelli U. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19. Eur Rev Med Pharmacol Sci. (2020) 24:4059–61.